167 related articles for article (PubMed ID: 32516245)
1. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K
Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245
[TBL] [Abstract][Full Text] [Related]
2. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
3. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
[TBL] [Abstract][Full Text] [Related]
4. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
5. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
6. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
7. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
8.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
[TBL] [Abstract][Full Text] [Related]
11. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
Nasir Z; Mahmood T; Adel H; Nausheen S; Hamid S; Sattar A; Manohar M
Cureus; 2019 Aug; 11(8):e5422. PubMed ID: 31632874
[TBL] [Abstract][Full Text] [Related]
12. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
[TBL] [Abstract][Full Text] [Related]
13. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
[TBL] [Abstract][Full Text] [Related]
14. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
15. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT
Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568
[TBL] [Abstract][Full Text] [Related]
16. Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma.
Ferdinandus J; Barbato F; Chodyla M; Fendler WP; Kessler L; Pomykala KL; Metzenmacher M; Krefting F; Hager T; Umutlu L; Herrmann K; Christoph DC
J Nucl Med; 2021 Feb; 62(2):191-194. PubMed ID: 32532926
[TBL] [Abstract][Full Text] [Related]
17. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
[TBL] [Abstract][Full Text] [Related]
19. The role of volumetric method in the assessment of chemotherapy response and predicting survival in malignant pleural mesothelioma.
Urfali FE; Metintas S; Gurgen A; Guntulu AK; Ozkan R; Metintas M
J Cancer Res Ther; 2021; 17(1):69-74. PubMed ID: 33723135
[TBL] [Abstract][Full Text] [Related]
20. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
